News
Academy
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Latest Executive Roundtables
  • Asembia 2025
  • Sales Effectiveness
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe
Advertisement

Industry Trends

>
  • IR Licensing and Partnerships

Latest News

CSL to Layoff 15% of Employees, Close 22 US-based Plasma Centers
CSL to Layoff 15% of Employees, Close 22 US-based Plasma Centers
By Don Tracy, Associate Editor

August 19th 2025

The global biotherapeutics company announced that it will seek to streamline operations as part of a broader transformation to boost efficiency, refocus on core businesses, and reinvest in high-priority programs.

Layoffs Continue Across Biotech Industry as More Companies Restructure and Reprioritize
Layoffs Continue Across Biotech Industry as More Companies Restructure and Reprioritize
By Don Tracy, Associate Editor

August 14th 2025

Fate Therapeutics, Generation Bio, and ORIC Pharmaceuticals join a growing list of companies implementing workforce reductions as they restructure operations, extend cash runways, and focus resources on advancing lead clinical programs amid challenging market conditions.

AbbVie Latest to Commit to New US Manufacturing Growth Projects, Committing $195 Million to Expand API Capabilities
AbbVie Latest to Commit to New US Manufacturing Growth Projects, Committing $195 Million to Expand API Capabilities
By Don Tracy, Associate Editor

August 13th 2025

The project aims to enhance AbbVie’s chemical synthesis capacity to support next-generation neuroscience, immunology, and oncology medicines, with construction beginning in 2025 and operations slated for 2027.

Bayer Layoffs Reach 12,000 in Ongoing $2.3 Billion Restructuring Plan
Bayer Layoffs Reach 12,000 in Ongoing $2.3 Billion Restructuring Plan
By Don Tracy, Associate Editor

August 7th 2025

The company is streamlining its global workforce as part of a multi-year cost-cutting strategy, while raising its 2025 outlook on the strength of key pharmaceutical products.

Stephanie J. Creary, Assistant Professor of Management at The Wharton School of The University of Pennsylvania.
How Should BioPharma C-Suites Guide and Support Remaining Employees After Workforce Reductions?
By Michael Wong

August 5th 2025

A Harvard Business School Healthcare Alumni Association Q&A with Stephanie J. Creary, Assistant Professor of Management at The Wharton School of The University of Pennsylvania.

More News


Site Logo

Health Innovation: Institutionalizing the Teachable Moment with GENiE

William Looney
May 13th 2015

William Looney reports on last week's Global Educators Network for Health Care Innovation Education meeting, focused on shared learning and best practices to drive reforms in both the public and private sectors.


peter-young.jpg

A Wild Ride: Biotech Financial and M&A Trends 2014

Peter Young
March 10th 2015

Peter Young examines the positive drivers affecting the biotech industry and what happened on the M&A, IPO and financial fronts in biotech in 2014 - and what to expect in 2015.


Site Logo

Heart Failure Health Area Wide Open for New Therapeutics

Josh Baxt
February 9th 2015

The heart failure health area is set to expand from $2.9 billion in 2013 to $8.9 billion in 2023, writes Josh Baxt.


Message from Morgan: Takeaways from 2015's J.P. Morgan Conference

Message from Morgan: Takeaways from 2015's J.P. Morgan Conference

William Looney
February 3rd 2015

This year's J.P. Morgan Conference in San Francisco showed that smaller “stealth pharma” players are beginning to show solid organic growth. William Looney reports.


Beyond the Blame Game: How Pharma is Learning to Collaborate

Beyond the Blame Game: How Pharma is Learning to Collaborate

Jesper Hoiland
January 13th 2015

In a follow-up to our November CEO profile, Novo Nordisk’s Jesper Høiland writes how pharma companies and insurers are learning to collaborate.


How the "Millennials" Demographic is Shaping US Healthcare

How the "Millennials" Demographic is Shaping US Healthcare

William Looney
October 6th 2014

The US is skewing young again, and the "millennials" have the clout to color everything from the nation's cultural landscape to the conduct of business practices like marketing and customer engagement, writes Bill Looney.


Pharm Exec's 13th Annual Industry Audit

Pharm Exec's 13th Annual Industry Audit

Bill Trombetta
September 1st 2014

After a dip into negative territory in 2012, 2013 delivered a resurgence in sales revenues, but the turnaround only spotlights a larger trend: the growing divide between the big Pharmas and the more nimble players.


A Window on the Industry: The Emerging Pharma Leaders 2014

A Window on the Industry: The Emerging Pharma Leaders 2014

William Looney
August 1st 2014

Pharm Exec's 2014 roster of emerging pharma leaders serves as a window on work in an industry that relies on human capital as the coinage of success, writes William Looney.


The Peace Dividend

The Peace Dividend

William Looney
July 10th 2014

A surprising takeaway from the recent BIO Convention, writes William Looney, is the stark contrast between cooperative industry engagement and an unstable geopolitical order.


Pharma 50 Trends: Past, Present, and Future

Pharma 50 Trends: Past, Present, and Future

William Looney
June 9th 2014

Finding the correct coordinates for big Pharma's endless cycle of re-positioning is just as important as a winning scientific hand, writes William Looney.


Pharm Exec's Pharma 50 2014

Pharm Exec's Pharma 50 2014

Waseem Noor
June 9th 2014

For those companies in this year's Pharm Exec Top 50, meeting the accelerating market demand for specialty products has become an acute strategic imperative.


2014 Brand of the Year

2014 Brand of the Year

Ben Comer;William Looney
May 1st 2014

Pharm Exec's Brand of the Year recipients for 2014 are multiple sclerosis treatment Copaxone and KORLYM for diseases driven by excess production of the metabolic hormone, cortisol. We profile the journey of both drugs.


Population Health: The Call to Community

Population Health: The Call to Community

William Looney
March 11th 2014

Population health is the foundation for much of what is truly new in US health reform. Pharm Exec talks to Dr. David Nash, Dean of the Jefferson Medical University School of Population Health.


What Do Pharma's "High Performers" Have in Common?

What Do Pharma's "High Performers" Have in Common?

March 7th 2014

A study of high-performing pharma companies reveals science-based innovation strategies and patient-outcome-based commercial models are now the key drivers of growth.


Pharm Exec: Annual Press Audit 2014

Pharm Exec: Annual Press Audit 2014

Stephen J. Porth, PhD;George P. Sillup, PhD
March 3rd 2014

Pharm Exec's latest survey of press issues shows that media coverage continues to remain on balance negative toward the industry, by a slight margin: 47% this year compared to a 46% average over the last seven years.


Pharm Exec's Annual Industry Outlook 2014

Pharm Exec's Annual Industry Outlook 2014

Ben Comer;Julian Upton
January 21st 2014

For Big Pharma, the merits of strategic focus and operational discipline are more important than ever. It is time to be decisive - muddling through is so yesterday.


US Pharma Challenges 2014

US Pharma Challenges 2014

Jill Wechsler, Pharm Exec’s Washington Correspondent
January 8th 2014

Pricing and personalized medicine are key themes shaping drug development and marketing in the U.S. in 2014, writes Jill Wechsler.


2013 Pharma and Biotech Financial Report

2013 Pharma and Biotech Financial Report

Peter Young
December 1st 2013

Big Pharma and biotech continue to need each other. But biotech is feeling slightly more confident as the options for IPOs get better, writes Peter Young.


Top Medical Innovations for 2014

Top Medical Innovations for 2014

Ben Comer
November 1st 2013

At the conclusion of the Cleveland Clinic's Medical Innovations Summit each year, 10 innovative technologies are unveiled before the audience, and designated as new and revolutionary tools for the treatment of disease and disability.


Site Logo

Taking Stock: Notes on the Industry Audit

William Looney
October 1st 2013

Our October issue highlights a latent threat to Big Pharma: the behavioral mindset that may be best characterized as "ageing in place."


Pharm Exec's 2013 Emerging Pharma Leaders

Pharm Exec's 2013 Emerging Pharma Leaders

July 1st 2013

Meet the Emerging Pharma Leaders of 2013. These 15 trend setters represent the future of an industry that knows it must change: the question is how, and to what?


The 2013 Pharm Exec Top 50

The 2013 Pharm Exec Top 50

Waseem Noor
May 1st 2013

Patent expiries dampen revenues for some of the biggest Big Pharma, but growth continues unabated for a few nimble "stealth" players moving steadily up the list.


Site Logo

Brand of the Year: Januvia

Ben Comer
March 1st 2013

In 2012, Merck's diabetes franchise became the highest-selling product family in its 122-year history.


Industry Forecast 2013

Industry Forecast 2013

William Looney
January 25th 2013

As companies seek safety from empowered payers, bankrupt governments, and distracted regulators, success will come to those who understand how competition and technology are changing the way everything this industry does.


Transforming Drug Development: A Lilly–Covance Case Study

Transforming Drug Development: A Lilly–Covance Case Study

December 1st 2012

Eli Lilly's pioneering pact with leading CRO Covance made big news when it happened. Four years later, both parties can point to metrics that suggest the benefit is mutual.


Site Logo

Pharm Exec's 2013 Pipeline Report

Ben Comer
November 1st 2012

Is the 'lost decade' of declining pipeline productivity finally over? Our annual survey of analyst assessments of the state of drug development suggests so...


Pharm Exec's 11th Annual Industry Audit

Pharm Exec's 11th Annual Industry Audit

Bill Trombetta
September 1st 2012

Shareholder value now depends on finding pockets of "good" growth, in segments with fewer players, and where expenses can be tightly controlled.


Emerging Pharma Leaders 2012

Emerging Pharma Leaders 2012

PE Staff
July 1st 2012

Meet the rest of 2012's Emerging Pharma Leaders. Can these 15 global trend setters set the mark on their time in history?


Site Logo

From the Editor:The Connections Game

William Looney
June 1st 2012

As the old Broadway song goes, June is busting out all over-and true to the season this month's issue stretches the seams with content that ranges from the sublime to the ridiculous.


Pharma 50 Comment: Seeding Beyond the Base

Pharma 50 Comment: Seeding Beyond the Base

William Looney
May 1st 2012

The industry's reputation as a growth industry no one wants to pay for is more secure than ever, writes Pharm Exec Editor William Looney.

<1
...
131415161718>
About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.